High‐throughput ultra‐high‐performance liquid chromatography/tandem mass spectrometry quantitation of insulin‐like growth factor‐I and leucine‐rich α‐2‐glycoprotein in serum as biomarkers of recombinant human growth hormone administration

Authors

R.G. Kay
C. Barton
C.P. Velloso
P.R. Brown
C. Bartlett
Anthony Blazevich, Edith Cowan UniversityFollow
R.J. Godfrey
G. Goldspink
R. Rees
G.R. Ball
D.A. Cowan
S.D. Harridge
J. Roberts
P. Teale
C.S. Creaser

Document Type

Journal Article

Keywords

growth hormone, IGF-I, biomarker

Publisher

Wiley

Faculty

Faculty of Computing, Health and Science

School

School of Exercise, Biomedical and Health Science / Centre for Exercise and Sports Science Research

RAS ID

8909

Comments

Kay, R. G., Barton, C., Velloso, C. P., Brown, P. R., Bartlett, C., Blazevich, A. J., ... & Cowan, D. A. (2009). High‐throughput ultra‐high‐performance liquid chromatography/tandem mass spectrometry quantitation of insulin‐like growth factor‐I and leucine‐rich α‐2‐glycoprotein in serum as biomarkers of recombinant human growth hormone administration. Rapid Communications in Mass Spectrometry, 23(19), 3173-3182. Available here

Abstract

Insulin-like growth factor-I (IGF-I) is a known biomarker of recombinant human growth hormone (rhGH) abuse, and is also used clinically to confirm acromegaly. The protein leucine-rich α-2-glycoprotein (LRG) was recently identified as a putative biomarker of rhGH administration. The combination of an ACN depletion method and a 5-min ultra-high-performance liquid chromatography/tandem mass spectrometry (uHPLC/MS/MS)-based selected reaction monitoring (SRM) assay detected both IGF-I and LRG at endogenous concentrations. Four eight-point standard addition curves of IGF-I (16–2000 ng/mL) demonstrated good linearity (r² = 0.9991 and coefficients of variance (CVs)